泰凌醫藥(01011.HK):"氨溴索"或具有治療新型冠狀病毒的潛力
格隆匯1月29日丨泰凌醫藥(01011.HK)公告,公司關注國內新聞平台《澎湃新聞》於日期為2020年1月28日的報導,有關報導指“氨溴索",以沐舒坦為人們所熟知,是一種呼吸道潤滑祛痰藥臨牀上常用於急慢性支氣管炎等疾病。如今,中國科學家通過人工智能藥靶篩選,發現其具有治療新型冠狀病毒(2019-nCoV)的潛力”。
同時,根據上述報導,“北京大學基礎醫學院副教授初明在接受《中國科學報》採訪時表示,經過全面考慮,他們認為沐舒坦毒副作用較低,還是一種呼吸科常用藥物,可考慮最先在臨牀治療中觀察”。
公司附屬公司-蘇州第壹製藥有限公司擁有卓澳,一種"氨溴索"-(沐舒坦)的藥物,公司將緊密注視新型冠狀病毒(2019-nCoV)的治療方法進程,一經確認"氨溴索"-(沐舒坦)能有效治療新型冠狀病毒,公司的生產部門將全力配合中國政府大量生產卓澳,一種"氨溴索"-(沐舒坦)的藥物,以供應市場需要,與國家及人民一同全力抗疫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.